Brainsway

Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction

BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS)

BrainsWay's (BWAY) CEO Christopher von Jako on Q4 2020 Results - Earnings Call Transcript

Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET

BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights

CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its fourth quarter and full year 2020 financial results as well as operational highlights after the close of the financial markets on Wednesday, March 24, 2021. The Company will host a conference call and webcast on Thursday, March 25, 2021 at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

CRESSKILL, N.J. and JERUSALEM, March 08, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 31st Annual Healthcare Conference taking place on March 16-18, 2021. The Company will also host one-on-one investor meetings at the conference.

BrainsWay to Present at the Oppenheimer 31st Annual Healthcare Conference

CRESSKILL, N.J. and JERUSALEM, March 01, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced the closing of its previously announced underwritten public offering of 5,315,300 American Depositary Shares (“ADSs”), upsized to include 693,300 ADSs sold pursuant to the underwriters' exercise in full of their option to purchase additional ADSs, at a price to the public of $8.50 per ADS. The gross proceeds to BrainsWay from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $45.2 million.

BrainsWay Ltd. Announces Closing of $45.2 Million Underwritten Public Offering of American Depositary Shares Including Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

CRESSKILL, N.J. and JERUSALEM, Feb. 22, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it intends to offer American Depositary Shares, each representing two ordinary shares, in an underwritten public offering. BrainsWay also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the American Depositary Shares sold in the offering. All of the American Depositary Shares, and the underlying ordinary shares, will be offered by BrainsWay. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BrainsWay Ltd. Announces Proposed Public Offering of American Depositary Shares

CRESSKILL, N.J. and JERUSALEM, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced the addition of Fran Hackett as Vice President of North American Sales effective February 16, 2021.

BrainsWay Enhances Commercial Leadership Team with the Addition of Fran Hackett as Vice President of North American Sales

Following Historic Abraham Accords, Israel's Deep Transcranial Magnetic Stimulation (Deep TMS) Treatment to Come to the United Arab Emirates Following Historic Abraham Accords, Israel's Deep Transcranial Magnetic Stimulation (Deep TMS) Treatment to Come to the United Arab Emirates

BrainsWay Signs Exclusive Distribution Agreement with Gaelan Medical Trade LLC

FDA clearance for smoking cessation moves Brainsway towards a portfolio of neurological disorder treatments and extends the company's competitive advantage. The publication of positive real-world results for treating OCD adds support to the case for insurance reimbursement, although cost effectiveness is still a potential barrier.

Brainsway: Still Undervalued

Brainsway Ltd. (BWAY) CEO Chris von Jako on Q3 2020 Results - Earnings Call Transcript

Monday, November 23, 2020, at 10:00 AM Eastern Time Monday, November 23, 2020, at 10:00 AM Eastern Time

BrainsWay Hosting Key Opinion Leader Call on Deep Transcranial Magnetic Stimulation for Treating Psychiatric Disorders

CRESSKILL, N.J. and JERUSALEM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its third quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 18, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

BrainsWay to Report Third Quarter 2020 Financial Results and Operational Highlights on November 18, 2020

In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder In conjunction with OCD Awareness Week, BrainsWay partners with mental health influencers and patients to increase education around misrepresentation of the disorder

BrainsWay Debuts “#TheRealOCD” Campaign and Video on Obsessive-Compulsive Disorder (OCD)

Deep TMS highlighted in 10 presentation posters at annual session Deep TMS highlighted in 10 presentation posters at annual session

BrainsWay’s Deep TMS Takes Center Stage at Clinical TMS Society Annual Poster Session

CRESSKILL, N.J. and JERUSALEM, Israel, Sept.  08, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 22 at 1:40 PM ET.

BrainsWay to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

As of late, it has definitely been a great time to be an investor in Brainsway.

Brainsway's Shares March Higher, Can It Continue?

CRESSKILL, N.J. and JERUSALEM, Sept.  02, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

BrainsWay Announces Presentations at Upcoming Investor Conferences

Brainsway (BWAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Brainsway (BWAY) Jumps: Stock Rises 7.5%

Brainsway’s current valuation is low as a result of a decline in revenue due to COVID-19 lockdowns.s

Brainsway: Lockdowns Are Hiding Progress In The Business

Brainsway (BWAY) news for Monday includes approval from the U.S. Food & Drug Administration (FDA) sending BWAY stock higher.

Brainsway News: BWAY Stock Surges 16% on FDA Approval of Smoking Addiction System

Company Intends to Execute a Controlled U.S. Market Release in Early 2021

BrainsWay Receives FDA Clearance for Smoking Addiction in Adults

BrainsWay Ltd. (BWAY) CEO Christopher von Jako on Q2 2020 Results - Earnings Call Transcript

Shares of Brainsway (NASDAQ:BWAY) remained unaffected after the company reported Q2 results.

Brainsway: Q2 Earnings Insights

CRESSKILL, N.J. and JERUSALEM, Israel, Aug.  12, 2020  (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today reported financial results for the quarter ended June 30, 2020, and provided an operational update.

News for Brainsway Stock (BWAY)